Advertisement

Topics

Companies Related to "Small Molecule Shows Marked Activity Against Ibrutinib Resistant" [Most Relevant Company Matches] RSS

17:51 EDT 15th June 2019 | BioPortfolio

Here are the most relevant search results for "Small Molecule Shows Marked Activity Against Ibrutinib Resistant" found in our extensive corporate database of over 50,000 company records.

Showing "Small Molecule Shows Marked Activity Against Ibrutinib Resistant" Companies 1–25 of 2,500+

Relevant

Avalon Pharmaceuticals

Avalon Pharmaceuticals' primary mission is to discover and develop innovative small molecule therapeutics using cutting-edge genomic technologies. Through its comprehensive genomics approach, Avalon is able to pinpoint proprietary drug activity markers and drug targets and to use these for drug screening in complex biological systems, facilitating the identification of lead drug candidates. Avalon...


Scion Pharmaceuticals

Scion is focused on identifying and optimizing small-molecule drugs for the treatment of central nervous system (CNS) disorders and cardiovascular diseases. Scion's automated electrophysiology technology platform -- High-Throughput ElectroPhysiology, or HTEP -- permits the rapid discovery of small molecule drugs that modulate ion channels and receptors. Using HTEP assay technology, Scion can rapid...

Expansion Therapeutics, Inc.

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at The Scripps Research Institute, Expansion has assembled the intellectual property, know-how, ...


PolyMedix Inc.

PolyMedix is a publicly traded emerging biotechnology company focused the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drug candidates that mimic the activity of proteins. The Company’s antibioti...

PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of serious acute cardiovascular disorders and infectious diseases. PolyMedix uses a rational drug design approach to create non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. PMX-60056, ...

Calyx Therapeutics

Calyx Therapeutics uses novel methods to isolate the biologically active molecule from natural plant and animal extracts with demonstrated clinical activity in humans. The company determines the chemical structure of the isolated compound and develops small-molecule analogs for pharmaceutical applications. Calyx is pursuing drug discovery efforts in the areas of diabetes, inflammation and allerg...

Infinity Pharmaceuticals

The mission of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. We have built a pipeline of innovative product candidates for multiple cancer indications, all of which represent proprietary applications of our expertise in small molecule drug technologies. We believe that our s...

Aragon Pharmaceuticals Inc.

Aragon Pharmaceuticals is a privately held small-molecule drug discovery company identifying breakthrough medicines for the treatment of hormonally driven cancers. These cancers are traditionally treated with anti-hormonal therapies but often become resistant, and follow-on therapies are largely ineffective. The company plans to initiate a clinical trial with its lead compound, ARN-509, in patient...

OnKure

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenv...

OnKure, Inc.

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenv...

Locus Discovery Incorporated

Locus Discovery Inc. is a privately held chemogenomics biopharmaceutical company organized in September 1999, and is based on technology exclusively licensed from the Sarnoff Corporation (SRI International). The Locus Discovery process is a novel computational approach for rapidly designing small molecule therapeutic compounds that can act as antagonists or agonists of protein activity.

X-Biotix Therapeutics, Inc.

X-Biotix is a discovery, early preclinical-stage company that was spun out of X-Chem and incorporated in 2016, with a focus on delivering the next generation of antibiotics to combat multi-drug resistant Gram-negative pathogens. The company, located in Waltham, MA, is undertaking a multi-target discovery strategy to rapidly identify and validate novel smal...

ProteoTech Inc.

ProteoTech is a privately-held, drug development company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolded protein disorders and amyloid diseases. ProteoTech’s lead small molecule drug, Systebryl™ (PTI-110), will soon be entering a Phase 1/2 proof-of-concept clinical trial in patients with AL (immunoglobulin ...

Deciphera Pharmaceuticals, LLC

Deciphera Pharmaceuticals is a drug discovery and development company whose objective is to design, optimize, and introduce small molecule therapeutics for human clinical trials and the global pharmaceutical marketplace. The company business focuses on the development of small molecule drug candidates which correct the molecular basis of human disease by regulating protein shape.

Cubist Pharmaceuticals

Cubist Pharmaceuticals Incorporated is a drug company focused on the discovery, development and commercialization of novel drugs to treat infections. Daptomycin, the Company's in-licensed lead product, is a unique agent with bactericidal activity that addresses the critical need for new antibiotics with potent activity against life threatening infections. Cubist Pharmaceuticals began Phase III cli...

HitGen Inc.

HitGen is a rapidly growing biotech company with headquarter and main research facility based in Chengdu, China and with a subsidiary in the USA. HitGen has established a platform for small molecule drug discovery research centred on the design, synthesis and screening of DNA encoded chemical libraries (DELs). HitGen’s DELs contain over 400 billion novel, ...

Ariana Pharmaceuticals

Ariana® pharmaceuticals is a drug discovery company focusing on accelerating discovery and development of novel, small molecule drug therapies using its proprietary multiparametric decision support technologyAriana has developed KEM™ (Knowledge Management and Extraction), a proprietary decision support technology for the rapid identification and optimisation of novel small molecule drug therapi...

Array BioPharma

Array BioPharma is a drug discovery company inventing new small molecule drugs through the integration of chemistry, biology and informatics. Our experienced scientists use the Array Discovery Platform, our integrated set of drug discovery technologies, to invent novel small molecule drugs in collaboration with leading pharmaceutical and biotechnology companies and to build our own pipeline of pro...

Avidex Limited

At Avidex, our focus is on the development of small molecule and protein therapeutics involving T cell receptors – either as drug targets or as the therapeutic molecule. Avidex has two key programmes leading to novel treatments in cancer, inflammation and autoimmune diseases.

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. A Phase 1B clinical trial evaluating its oral small molecule checkpoint inhib...

Microbiotix, Inc.

Microbiotix, Inc. is a privately held, product-focused biopharmaceutical company engaged in the research and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company currently has four novel compound series in research and development. Microbiotix currently has in development MBX 500, the first antibiotic that targets the DNA po...

U.S. Genomics

U.S. Genomics is pioneering tools to enable single molecule biology for the life sciences industry. The company develops and manufactures instruments and their associated reagents for researchers in academia, pharmaceutical and biotech companies, and contract research organizations. U.S. Genomics has introduced the Trilogy™2020 single molecule analyzer, a bench-top instrument, combining advance...

Genta Incorporated

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead com...

NeoGenisis Drug Discovery Incorporated

We are focused on the discovery of small molecule drugs on a proteome and genome-wide scale. We believe that we are the only company currently capable of delivering small molecule drug candidates for virtually every medically important protein encoded by the human genome and that the rate at which we are forming discovery alliances validates the vast opportunity presented by the convergence of our...

Tres Mares Group

Miler Lagos was born in Bogota in 1973. He has had solo shows in the U.S., Puerto Rico, Mexico, Bogota, and group shows all over Latin America, UK, France and Germany.


More From BioPortfolio on "Small Molecule Shows Marked Activity Against Ibrutinib Resistant"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks